A Gomez-Lumbreras1, P Ferrer2, E Ballarín3, M Sabaté4, X Vidal4, M Andretta5, A Coma6, L Ibáñez7. 1. IDIAP Jordi Gol, Medicines Research Unit, Barcelona, Spain; Fundació Institut Català de Farmacologia, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. 2. Fundació Institut Català de Farmacologia, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. 3. Hospital Universitari Vall d'Hebron, Barcelona, Spain; Fundació Institut Català de Farmacologia, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain. 4. Hospital Universitari Vall d'Hebron, Barcelona, Spain; Fundació Institut Català de Farmacologia, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain; Department of Clinical Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain. 5. Coordinamento Unico sul Farmaco, Veneto Region, Italy. 6. Pharmacy Department of Barcelona Health Region, Catalan Health Service (CatSalut), Barcelona, Spain. 7. Hospital Universitari Vall d'Hebron, Barcelona, Spain; Fundació Institut Català de Farmacologia, Passeig de la Vall d'Hebron, 119-129, 08035, Barcelona, Spain; Department of Clinical Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Bellaterra, Spain. Electronic address: libanez@uab.cat.
Abstract
BACKGROUND: We aimed at describing the trends in antidepressants use (AD) by age and sex, during 2007-2011, in 5 European settings (Sweden, Norway, Denmark, Catalonia and Veneto), and to assess whether the differences found across settings could be related to economic, social and cultural determinants. METHODS: We collected data of AD use expressed in defined daily doses (DDD). Data were retrieved from population-based databases. We calculated DDD/1000 inhabitants/day. We analysed which economic, social, and cultural covariates determined between-settings differences in AD consumption. RESULTS: The use of AD showed an increasing trend during the study period, being Selective Serotonin Reuptake Inhibitors the most consumed, followed "others AD". Women and the elderly showed the highest AD consumption. Between-settings variability in AD consumption showed a positive correlation with pharmaceutical expenditure and a negative one with general practitioner's rate. After adjusting by pharmaceutical expenditure and general practitioners rate Masculinity, Long-Term Orientation and Individualism cultural dimensions were associated with AD use by using the Hofstede´s cultural dimensions model. LIMITATIONS: This study has been conducted in administrative databases, with no information on AD use by indication; differences among AD use could be related to their prescription for other disorders. Analyses were based on a small dataset and none of the results reached statistical significance. CONCLUSIONS: AD use increased through 2007-2011. Pharmaceutical expenditure and General Practitioners rate, Masculinity, Long-Term Orientation and Individualism explained the differences in AD use between countries. People's attitude should be considered when designing national campaigns to improve antidepressant use.
BACKGROUND: We aimed at describing the trends in antidepressants use (AD) by age and sex, during 2007-2011, in 5 European settings (Sweden, Norway, Denmark, Catalonia and Veneto), and to assess whether the differences found across settings could be related to economic, social and cultural determinants. METHODS: We collected data of AD use expressed in defined daily doses (DDD). Data were retrieved from population-based databases. We calculated DDD/1000 inhabitants/day. We analysed which economic, social, and cultural covariates determined between-settings differences in AD consumption. RESULTS: The use of AD showed an increasing trend during the study period, being Selective Serotonin Reuptake Inhibitors the most consumed, followed "others AD". Women and the elderly showed the highest AD consumption. Between-settings variability in AD consumption showed a positive correlation with pharmaceutical expenditure and a negative one with general practitioner's rate. After adjusting by pharmaceutical expenditure and general practitioners rate Masculinity, Long-Term Orientation and Individualism cultural dimensions were associated with AD use by using the Hofstede´s cultural dimensions model. LIMITATIONS: This study has been conducted in administrative databases, with no information on AD use by indication; differences among AD use could be related to their prescription for other disorders. Analyses were based on a small dataset and none of the results reached statistical significance. CONCLUSIONS:AD use increased through 2007-2011. Pharmaceutical expenditure and General Practitioners rate, Masculinity, Long-Term Orientation and Individualism explained the differences in AD use between countries. People's attitude should be considered when designing national campaigns to improve antidepressant use.
Authors: Leon Alexander Mclaren Berge; Bettina Kulle Andreassen; Jo S Stenehjem; Trond Heir; Kari Furu; Asta Juzeniene; Ingrid Roscher; Inger Kristin Larsen; Adele C Green; Marit B Veierød; Trude E Robsahm Journal: Clin Epidemiol Date: 2020-02-21 Impact factor: 4.790